Opus Genetics, Inc. (IRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $384.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Opus Genetics, Inc. (IRD) Earnings: Report Dates and Results
Opus Genetics (IRD) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Opus Genetics reported EPS of -$0.18, below the -$0.14 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IRD has an expected report date of Mar 8, 2027.
Earnings History
Of the 36 quarters below that had an estimate, IRD beat 16, missed 13 and matched 7. Revenue for the quarter ended Sep 30, 2026 was $1.14M, down 63.0% from $3.08M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.18 | -$0.14 | -$0.21 - -$0.09 | -28.57% | Miss | N/A | 12 | 1 up, 0 down | Nov 10, 2026 | $1.14M |
| Jun 30, 2026 | -$0.14 | -$0.15 | -$0.27 - -$0.09 | +6.67% | Beat | N/A | 13 | 0 up, 1 down | Aug 6, 2026 | $755000 |
| Mar 31, 2026 | -$0.75 | -$0.14 | -$0.18 - -$0.09 | -435.71% | Miss | N/A | 6 | 0 up, 1 down | May 12, 2026 | $2.16M |
| Dec 31, 2025 | -$0.21 | -$0.12 | N/A | -78.27% | Miss | N/A | 3 | 0 up, 0 down | Feb 25, 2026 | $3.87M |
| Sep 30, 2025 | -$0.25 | -$0.13 | -$0.13 - -$0.13 | -92.31% | Miss | N/A | 1 | 0 up, 0 down | Nov 12, 2025 | $3.08M |
| Jun 30, 2025 | -$0.12 | -$0.26 | N/A | +53.85% | Beat | N/A | N/A | N/A | Aug 13, 2025 | $2.88M |
| Mar 31, 2025 | -$0.32 | -$0.34 | N/A | +5.88% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2025 | $4.37M |
| Dec 31, 2024 | -$1.27 | -$0.05 | -$0.34 - $0.55 | N/A | N/A | N/A | 3 | 0 up, 2 down | Mar 31, 2025 | $4.30M |
| Sep 30, 2024 | -$0.29 | -$0.23 | N/A | -26.09% | Miss | -216.0% | N/A | N/A | Nov 12, 2024 | $3.87M |
| Jun 30, 2024 | -$0.30 | -$0.28 | N/A | -7.14% | Miss | N/A | N/A | N/A | Aug 13, 2024 | $1.11M |
| Mar 31, 2024 | -$0.29 | -$0.14 | N/A | -107.14% | Miss | N/A | N/A | N/A | May 10, 2024 | $1.71M |
| Dec 31, 2023 | -$0.21 | -$0.05 | N/A | -320.00% | Miss | -112.4% | N/A | N/A | Mar 8, 2024 | $1.69M |
| Sep 30, 2023 | $0.25 | -$0.23 | N/A | +208.70% | Beat | N/A | N/A | N/A | Nov 13, 2023 | $11.94M |
| Jun 30, 2023 | -$0.24 | -$0.24 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 11, 2023 | $3.67M |
| Mar 31, 2023 | -$0.28 | -$0.16 | N/A | -75.00% | Miss | N/A | N/A | N/A | May 15, 2023 | $1.75M |
| Dec 31, 2022 | $1.69 | $1.00 | N/A | +69.00% | Beat | N/A | N/A | N/A | Mar 31, 2023 | $39.85M |
| Sep 30, 2022 | -$0.22 | -$0.29 | N/A | +24.14% | Beat | N/A | N/A | N/A | Nov 4, 2022 | N/A |
| Jun 30, 2022 | -$0.25 | -$0.33 | N/A | +24.24% | Beat | N/A | N/A | N/A | Aug 12, 2022 | N/A |
| Mar 31, 2022 | -$0.35 | -$0.35 | N/A | 0.00% | In line | N/A | N/A | N/A | May 13, 2022 | N/A |
| Dec 31, 2021 | -$0.35 | -$0.35 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 31, 2022 | N/A |
| Sep 30, 2021 | -$0.25 | -$0.36 | N/A | +30.56% | Beat | N/A | N/A | N/A | Nov 12, 2021 | $489000 |
| Jun 30, 2021 | -$0.52 | -$0.41 | N/A | -26.83% | Miss | N/A | N/A | N/A | Aug 12, 2021 | $100000 |
| Mar 31, 2021 | -$0.47 | -$0.83 | N/A | +43.37% | Beat | N/A | N/A | N/A | May 7, 2021 | N/A |
| Dec 31, 2020 | -$4.70 | -$4.70 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | -$0.33 | -$0.33 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 4, 2020 | N/A |
| Jun 30, 2020 | -$2.50 | -$2.48 | N/A | -0.81% | Miss | N/A | N/A | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.58 | -$0.60 | N/A | +3.33% | Beat | N/A | N/A | N/A | May 18, 2020 | N/A |
| Dec 31, 2019 | -$1.86 | -$2.00 | N/A | +7.00% | Beat | N/A | N/A | N/A | Mar 16, 2020 | N/A |
| Sep 30, 2019 | -$1.96 | -$1.96 | N/A | 0.00% | In line | N/A | N/A | N/A | Dec 27, 2019 | N/A |
| Jun 30, 2019 | -$2.44 | -$2.44 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 7, 2019 | N/A |
| Mar 31, 2019 | -$4.07 | -$0.93 | N/A | -337.63% | Miss | N/A | N/A | N/A | May 13, 2019 | N/A |
| Dec 31, 2018 | -$4.32 | -$4.32 | N/A | +0.04% | Beat | N/A | N/A | N/A | Mar 8, 2019 | N/A |
| Sep 30, 2018 | -$8.16 | -$8.16 | N/A | +0.04% | Beat | N/A | N/A | N/A | Nov 5, 2018 | N/A |
| Jun 30, 2018 | -$5.76 | -$0.17 | N/A | N/A | N/A | -400.0% | N/A | N/A | Aug 6, 2018 | N/A |
| Mar 31, 2018 | -$3.36 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2018 | N/A |
| Dec 31, 2017 | -$5.76 | -$6.72 | N/A | +14.32% | Beat | N/A | N/A | N/A | Mar 13, 2018 | N/A |
| Sep 30, 2017 | -$1.92 | -$10.24 | N/A | +81.25% | Beat | N/A | N/A | N/A | Nov 6, 2017 | N/A |
| Jun 30, 2017 | $1.92 | -$10.08 | N/A | +119.05% | Beat | N/A | N/A | N/A | Aug 7, 2017 | N/A |
| Mar 31, 2017 | -$43.20 | -$8.00 | N/A | -440.00% | Miss | N/A | N/A | N/A | May 5, 2017 | N/A |
| Dec 31, 2016 | -$1.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 27, 2017 | N/A |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.90, after -$2.15 the year before. It was -$21.23 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.90 | N/A |
| Dec 31, 2024 | -$2.15 | N/A |
| Dec 31, 2023 | -$0.48 | -155.2% |
| Dec 31, 2022 | $0.87 | N/A |
| Dec 31, 2021 | -$1.59 | N/A |
| Dec 31, 2020 | -$8.11 | N/A |
| Dec 31, 2019 | -$10.33 | N/A |
| Dec 31, 2018 | -$21.60 | N/A |
| Dec 31, 2017 | -$48.96 | N/A |
| Dec 31, 2016 | -$21.23 | N/A |
Frequently Asked Questions About IRD
When is Opus Genetics's next earnings date?
Opus Genetics's next earnings report is expected for Mar 8, 2027.
Did IRD beat earnings estimates last quarter?
No. Opus Genetics reported EPS of -$0.18 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 28.57%.
What EPS do analysts expect from IRD next quarter?
The consensus EPS estimate for Opus Genetics for the quarter ending Dec 31, 2026 is -$0.09 from 19 analysts, with estimates from -$0.19 to $0.20.
How often does IRD beat earnings estimates?
Opus Genetics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -74.32%.
IRD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors